Inocras Introduces MRDVision™: A Breakthrough in Ultra-Sensitive ctDNA Detection with Industry-Leading 1 ppm Sensitivity
Today, Inocras, a leader in whole genome sequencing (WGS) and advanced bioinformatics, unveiled MRDVision™, its groundbreaking solution for minimal residual disease (MRD) detection. Validated to CLIA standards, this innovative assay is now poised to transform clinical settings by setting a new benchmark in the detection of circulating tumor DNA (ctDNA). With an unprecedented simulated limit of detection (LOD) as low as 1 part per million (ppm), MRDVision™ offers unparalleled sensitivity, efficiency, and cost-effectiveness, empowering clinicians and researchers to track cancer recurrence and treatment response with unmatched precision.
Redefining MRD Testing with Whole Genome Sequencing and ppm-Level Sensitivity
MRDVision™ represents a paradigm shift in how MRD is detected and monitored. Unlike traditional assays that rely on limited gene panels, MRDVision™ integrates Inocras’s CancerVision™ WGS cancer profiling platform with Ultima Genomics’ ppmSeq™ technology to deliver a comprehensive, whole-genome approach. This unique combination enables continuous scanning of the entire cell-free DNA (cfDNA) genome, preserving valuable tumor insights without compressing data into restrictive panels.
By leveraging tumor whole genome-informed whole-genome cfDNA monitoring, MRDVision™ eliminates the need for patient-specific panels, streamlining workflows and reducing turnaround times. This innovative method ensures faster results, enhanced accuracy, and greater scalability—all while generating more actionable data per assay at a fraction of the cost of traditional panel-based tests.
Clinical Validation Demonstrates Superior Performance
In a recent clinical validation study using cfDNA samples from post-surgical ovarian and lung cancer patients, MRDVision™ demonstrated its industry-leading capabilities. The assay identified tumor-derived signals in 6% of cases that were missed by the comparator assay, likely due to its superior sensitivity at low tumor fractions. These findings align with MRDVision™’s analytical simulations, which established a simulated LOD95 of 1 ppm—a level of sensitivity achieved through high tumor mutational burden (TMB) tumors and plasma sequencing depths of 100x.
“MRDVision™ marks a paradigm shift in minimal residual disease detection,” said Jehee Suh, CEO of Inocras. “By delivering whole genome x whole genome analysis, this ultra-sensitive assay empowers clinicians to detect cancer recurrence earlier and assess therapy responses with greater precision. It has the potential to redefine the standard of care. Additionally, its robust data output supports a wide range of research applications, including drug development and biomarker discovery. Our streamlined, panel-free workflow makes this cutting-edge technology both scalable and cost-effective, enabling researchers to expand their studies without compromising quality.”
Key Advantages of MRDVision™
1. Ultra-Sensitive Detection
With a simulated LOD95 of 1 ppm, MRDVision™ sets a new standard for sensitivity in MRD testing. This level of precision ensures reliable detection of even the smallest traces of ctDNA, enabling earlier identification of cancer recurrence or progression.
2. High Concordance with Orthogonal Tests
Clinical validation studies demonstrate strong alignment between MRDVision™ and existing methods, while also detecting tumor-derived signals that other assays miss. This ensures consistent, reliable results across platforms.
3. Simplified Workflow and Rapid Turnaround
By eliminating the need for patient-specific panels, MRDVision™ simplifies workflows, reduces complexity, and delivers faster results. Clinicians can make timely, informed decisions to optimize patient care.
4. Cost-Effective Solution
MRDVision™ generates more data per assay at a lower cost compared to traditional panel-based tests. This affordability, combined with its scalability, makes it accessible for broader adoption in clinical and research settings.
Transforming Cancer Care and Research
The implications of MRDVision™ extend far beyond its technical capabilities. By enabling earlier detection of cancer recurrence and more precise monitoring of treatment responses, this assay has the potential to improve patient outcomes significantly. For researchers, MRDVision™ opens new avenues for exploring biomarkers, developing targeted therapies, and advancing personalized medicine.
The results of MRDVision™’s clinical validation will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 29, 2024. Attendees will have the opportunity to learn more about this groundbreaking technology and take advantage of a special promotional offer for the cancer research and clinician community. To learn more about this offer or schedule a consultation, contact Inocras today.
Why MRDVision™ Represents the Future of MRD Testing
As the demand for more sensitive and efficient MRD solutions continues to grow, MRDVision™ stands out as a game-changer in the field of oncology. Its ability to combine whole genome sequencing with ppm-level sensitivity addresses critical gaps in current technologies, offering a comprehensive, scalable, and cost-effective alternative.
For healthcare providers and researchers seeking to stay ahead in the fight against cancer, MRDVision™ provides a transformative tool that not only enhances diagnostic accuracy but also accelerates advancements in cancer care. By redefining the standard for MRD testing, Inocras is paving the way for a future where early detection and personalized treatment become the norm rather than the exception.
To explore how MRDVision™ can elevate your clinical practice or research initiatives, visit Inocras’ website or reach out to their team for more information. With MRDVision™, you’re not just adopting cutting-edge technology—you’re investing in a brighter future for cancer care.
